Insider · CIK 0001242116
Barbara K Finck
Files at FBRX (Forte Biosciences, Inc.), CMRA (Comera Life Sciences Holdings, Inc.). First filing Feb 14, 2023, latest Feb 14, 2023.
In brief
Barbara K Finck files SEC Form 4 as director at CMRA (Comera Life Sciences Holdings, Inc.), and also at FBRX (Forte Biosciences, Inc.). Since Feb 14, 2023, Barbara K Finck has reported 1 open-market buy worth $8,310 and 0 open-market sells worth $0, the latest filed on Feb 14, 2023.
A track record needs three past buys with six months of prices behind them; Barbara K Finck has 0, so none is measured yet.
The newest scored trade: bought $8,310 of CMRA on Jan 4, 2023, filed Feb 14, 2023, scored 44 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CMRA: Comera Life Sciences Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Comera Life Sciences Holdings, Inc. | $8,310 6,756 shares | +42% | +10% from low-85% from high |
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Stock Option (right to buy)]derivative | -166 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -31,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -18,353 | - | - | 0 | Aug 27, 2026 |
| Mar 19, 2025 | FBRX Forte Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Mar 21, 2025 |
| Aug 20, 2024 | FBRX Forte Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Aug 22, 2024 |
| Mar 21, 2024 | FBRX Forte Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 25, 2024 |
| Jan 4, 2023 | CMRA Comera Life Sciences Holdings, Inc. | POpen-market purchase Common Stock | +6,756 | $1.23 | $8,310 | 23,033 | Feb 14, 2023 |
| Jan 4, 2023 | CMRA Comera Life Sciences Holdings, Inc. | POpen-market purchase Warrant (Right to Buy)derivative | +6,756 | $0.25 | $1,689 | 6,756 | Feb 14, 2023 |
| Jan 4, 2023 | CMRA Comera Life Sciences Holdings, Inc. | AGrant or award Common Stock | +6,756 | $1.23 | $8,310 | 23,033 | Jan 6, 2023 |
| Jan 4, 2023 | CMRA Comera Life Sciences Holdings, Inc. | AGrant or award Warrants (right to buy)derivative | +6,756 | $0.25 | $1,689 | 6,756 | Jan 6, 2023 |
Questions about Barbara K Finck
Answered from the filings on this page, as of the latest one.
Is Barbara K Finck buying or selling?
Not in the last 12 months. Barbara K Finck's latest open-market trade on SEC Form 4 was bought $8,310 of CMRA on Jan 4, 2023.
How did Barbara K Finck's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Barbara K Finck has 0.
Where does Barbara K Finck file Form 4?
Barbara K Finck has filed Form 4 at CMRA (Comera Life Sciences Holdings, Inc.); FBRX (Forte Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.